Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WBA's upcoming earnings release on Thursday, October 13 will be closely monitored as many businesses struggle amid rising inflation and tougher operating environments. Investors will want to see some upbeat guidance more than anything else.

Walgreens Earnings Preview: Can WBA Stock Rebound?

Apple

Chevron

Disney

Home Depot

Intel

NIKE

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walmart

The market has remained volatile as Wall Street worries about a potential recession.

Jim Cramer goes over the best and worst Q3 performers in the Dow

PepsiCo

Expect a good read on a key part of the broader economy.

These 2 Consumer Stocks Could Move Markets This Week

Walgreens' upcoming Q4 FY22 results could miss estimates based on several risks including stronger-than-expected headwinds, inflation-driven declines in foot traffic, and further declines in the AllianceRx business. Possibly echoing these risks, Evercore ISI slashed their price target from $41.00 to $32.00 on October 3.

Walgreens: Potential Risks And Rewards Heading Into Q4 FY22 Earnings

If you want income, you're in the right spot, but if you want growth, you might want to look elsewhere.

2 Reasons to Buy Walgreens Stock, and 2 Reasons to Sell

On all metrics Walgreens appears extremely undervalued, trading near its P/B value, with great earnings yield, dividend yield, and stable earnings reports. Walgreens appears to be a screaming buy yielding a whopping 20.31% earnings yield and paying out a 6.27% dividend to investors.

Walgreens: Cheap, But Has Some Issues

Amcor Plc

Air Products and Chemicals

Franklin Resources

Essex Property Trust

Federal Realty Investment Trust

Coca-Cola

Leggett & Platt

Medtronic

Realty Income Corp

Stanley Black & Decker

T. Rowe Price Group

V.F.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of October 6, 2022 represented all eleven Morningstar Sectors. Broker estimated top-ten net gains ranged 24.27%-48.52% topped by VFC and SWK.

5 Top October Aristocrats, Which One To Buy?

At seven times forward earnings, a yield of close to 6%, and 46 years of dividend growth, Walgreens should be on investors' buy lists.

This Dividend Aristocrat With a 6% Yield Is a Screaming Bargain Right Now

Walgreens has fallen by 42% since the start of the year. The market appears to be overly-focused on short-term headwinds while ignoring transformation progress.

6%-Yielding Walgreens Is Now Ridiculously Cheap

Blackrock Inc

Citigroup

JPMorgan Chase & Co

Morgan Stanley

PNC Financial Services

UnitedHealth Group

U.S. Bancorp

Wells Fargo

The third quarter 2022 earnings season reporting officially kicks off next week with many big names in the financial world announcing their earnings, including JPMorgan Chase, Citigroup and more.

These Are The 10 Biggest Companies Revealing Earnings Next Week

Walgreens Boots Alliance WBA, -0.69% said Thursday that its stores will start selling over-the-counter Lexie Lumen hearing aids to adults starting Oct. 17. The aids costs $799 and are for adults with mild-to-moderate hearing loss.

Walgreens to start selling over-the-counter hearing aids this month

The pharmacy retailer hasn't made for a great investment over the past decade. Can that change?

Could Walgreens Stock Help You Retire a Millionaire?

Johnson & Johnson

York Water

Aged investors can sleep easy owning these rock-solid income stocks, which yield between 2% and 5.9%.

3 of the Safest Dividend Stocks Retirees Can Buy Right Now

Dow Inc

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."--DowJones&Co. Thirty Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net-gains ranged 26.17%-76.65% topped by BA 9/30/22.

Buy 4 October Dogs Of The Dow And Watch 4 More

FS KKR Capital Corp

Gilead Sciences

Kohl's

New York Community Bancorp

Prudential Financial

Being a Wall Street analyst is sometimes like being the local meteorologist on TV.

7 Big Dividend Stocks Wall Street Hates That Investors Should Love Now

Visa

The Dow Jones Industrial Average is comprised of 30 stocks -- three of which are plain-as-day bargains.

3 Dow Stocks That Are Screaming Buys in October

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced it is joining the Sustainable Medicines Partnership (SMP) as a founding sponsor of the initiative, which aims to collaborate and execute on projects to make the use of medicines more sustainable and less wasteful. Through its multi-stakeholder global collaboration with industry leaders such as Walgreens, the SMP is a four-year commitment to deliver evidence-based, integrated projects, including scalable solutions, frameworks, standards

Walgreens Joins Sustainable Medicines Partnership

Walgreens Boots Alliance Inc. ( WBA , Financial) operates the iconic drug store chains Walgreens in the U.S. and Boots in the U.K. The stock is now selling at close to 10-year lows, which could be an incredible value opportunity. However, a cheap stock can stay cheap forever if the company behind it never grows.

Is Walgreens Good Value Near 10-year lows?

And the distribution seems surprisingly safe.

Down 40%, This Well-Known Company Is Paying Its Highest Dividend Yield Ever

Drug store chain Walgreens is expanding a system of huge fulfillment centers — some as large as a city block — where robots package prescriptions for patients, The Wall Street Journal reported Sunday (Oct. 2).

Robots Fill Prescriptions at Walgreens Automated Fulfillment Centers

Walgreens Boots Alliance Inc. is turning to robots to ease workloads at drugstores as it grapples with a nationwide shortage of pharmacists and pharmacist technicians.

Walgreens will use robots to fill prescriptions to free up pharmacists

Chain says automated drug-filling centers cut pharmacist workloads by 25% and ease pressure on understaffed stores

Walgreens Turns to Prescription-Filling Robots to Free Up Pharmacists

With nearly 9,000 stores across the U.S., Walgreens offers strong total return potential.

This 5.8% Hyper-Yield Dividend Stock Is Great for Retirees

Ares Capital

Medical Properties Trust

Dividend Harvesting Week 82 Update: $8,200 Allocated, $596.65 In Annual Dividends Yielding 8.04% Across 79 Positions. The Dividend Harvesting portfolio has an 85.37% record of finishing the week in the black since its inception, 70/82 weeks.

Dividend Harvesting Week 82 Update: $8,200 Allocated, $596.65 In Annual Dividends Yielding 8.04% Across 79 Positions

These rock-solid dividend stocks have the tools and intangibles needed to deliver triple-digit total returns in five years.

News for Walgreens Stock (WBA)